CSF2 and melanoma: Recently a randomized, Phase III trial of talimogene laherparepvec or GM-CSF in patients (pts) with unresectable melanoma with regional or distant metastases (OPTiM) met its primary endpoint by improving durable response rates versus GM-CSF alone, and showed a tolerable safety profile (17).